Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $65.2 million.

  • Dexcom's Depreciation & Amortization (CF) rose 1280.28% to $65.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $251.8 million, marking a year-over-year increase of 1566.38%. This contributed to the annual value of $251.8 million for FY2025, which is 1566.38% up from last year.
  • As of Q4 2025, Dexcom's Depreciation & Amortization (CF) stood at $65.2 million, which was up 1280.28% from $63.6 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Depreciation & Amortization (CF) registered a high of $65.2 million during Q4 2025, and its lowest value of $20.9 million during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $45.9 million (2023), whereas its average is $45.7 million.
  • Per our database at Business Quant, Dexcom's Depreciation & Amortization (CF) surged by 8553.19% in 2022 and then grew by 22.94% in 2023.
  • Dexcom's Depreciation & Amortization (CF) (Quarter) stood at $32.1 million in 2021, then rose by 13.08% to $36.3 million in 2022, then skyrocketed by 44.63% to $52.5 million in 2023, then rose by 10.1% to $57.8 million in 2024, then rose by 12.8% to $65.2 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $65.2 million for Q4 2025, versus $63.6 million for Q3 2025 and $63.0 million for Q2 2025.